Urinary neopterin in patients with ovarian cancer

Pteridines

Volumn 17, Issue 4, 2006, Pages 145-153

  Melichar, Bohuslav ^a,b   Urbanek, Lubor ^a   Krcmová, Lenka ^a   Kalabova, Hana ^a   Svobodova, Iveta ^a   Dragounova, Emanuela ^a   Vesely, Pavel ^a   Hyspler, Radomír ^a   Solichova, Dagmar ^a  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Epithelial ovarian carcinoma; Metastasis; Neopterin; Ovary; Prognosis

Indexed keywords

CREATININE; LACTULOSE; MANNITOL; NEOPTERIN; PACLITAXEL; PLATINUM; SUCROSE; XYLOSE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTESTINE MUCOSA PERMEABILITY; LABORATORY TEST; LEUKOPENIA; NAUSEA; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; URINALYSIS; VOMITING;

EID: 33947430147     PISSN: 09334807     EISSN: 21954720     Source Type: Journal    
DOI: 10.1515/pteridines.2006.17.4.145     Document Type: Article

References (38)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer Statistics, 2004. CA Cancer J Clin 2004; 54: 8-29.
2. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
3. Piccart MJ, Bertelsen K, James K, et al. Randomized Intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000; 92: 699-708.
4. Wachter H, Fuchs D, Hausen A, Reibnegger G, Werner ER. Neopterin as marker for activation of cellular immunity: immunologic basis and clinical application. Adv Clin Chem 1989; 27: 81-141.
5. Huber C, Batchelor JR, Fuchs D, et al. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med 1984; 160: 310-316.
6. Melichar B, Solichová D, Freedman RS. Neopterin as an indicator of immune activation and prognosis in patients with gynecological malignancies. Int J Gynecol Cancer 2006; 16: 240-252.
7. Yada-Hashimoto N, Yamamoto T, Kamiura S, et al. Metastatic ovarian tumors: a review of 64 cases. Gyn Oncol 2003; 89: 314-317.
8. Melichar B, Solichova D, Melicharova K, Cermanova M, Urminska H, Ryska A. Systemic immune activation, anemia and thrombocytosis in breast cancer patients treated by doxorubicin and paclitaxel. Pteridines 2006; 17: in press.
9. Melichar B, Solichova D, Melicharova K, Malirova E, Cermanova M, Zadak Z. Urinary neopterin in patients with advanced colorectal carcinoma. Int J Biol Markers 2006; 21: 190-198.
10. Melichar B, Solichova D, Svobodova I, Urbanek L, Melicharova K. Urinary neopterin in patients with upper gastrointestinal, biliary and pancreatic carcinomas. Pteridines 2006; 17: 20-24.
11. Marth C, Weger E, Muller-Holzner E, et al. The prognostic value of nuclear roundness and neopterin in ovarian cancer. Eur J Cancer 1993; 29A: 1863-1868.
12. Park IS, Lee YS, Kim JC, Hwang SG. Serum neopterin levels in ovarian tumors. Int J Gynaecol Obstet 1995; 51: 229-234.
13. Melichar B, Urminská H, Kohlová T, Nová M, Cesák T. Brain metastases of epithelial ovarian carcinoma responding to cisplatin and gemcitabine combination chemotherapy: a case report and review of the literature. Gyn Oncol 2004; 94: 367-376.
14. Reibnegger G, Hetzel H, Fuchs D, et al. Clinical significance of neopterin for prognosis and follow-up in ovarian cancer. Cancer Res 1987; 47: 4977-4981.
15. Cermanová M, Melichar B, Solichová D, et al. Urinary neopterin and microalbuminuria in patients treated by low-density lipoprotein apheresis. Pteridines 2005; 16: 174-183.
16. Cibickova L, Cibicek N, Zdansky P, Kohout P. The impairment of gastroduodenal mucosal barrier by coffee. Acta Medica (Hradec Kralove) 2004; 47: 273-276.
17. Bichler A, Fuchs D, Hausen A, Hetzel H, Reibnegger G, Wachter H. Measurement of urinary neopterin in normal pregnant and non-pregnant women and in women with benign and malignant genital tract neoplasms. Arch Gynecol 1983; 233: 121-130.
18. Bartel U, Rabe H, Schulz-Pinkus M. Erste Erfahrungen mit Neopterinbestimmungen im Urin von Frauen mit Genital- und Mammatumoren. Zentrabl Gynakol 1987; 109: 1226-1232.
19. Melichar B, Zeimet A, Artner-Dworzak E, et al. Association between increased urinary zinc and neopterin concentrations in women with gynaecological cancer. TumorDiagn Ther 1993; 14: 110-112.
20. Avall Lundqvist E, Nordstrom L, Sjovall K, Eneroth P. Evaluation of seven different tumour markers for the establishment of tumour marker panels in gynecologic malignancies. Eur J Gynaecol Oncol 1989; 10: 395-405.
21. Szarka G, Pulay T, Csomor S, Tran-Phoung-Mai, Schumann B. The significance of neopterin determination as a tumour marker in ovarian cancer. Acta Chir Hung 1988; 29: 359-364.
22. Fuith LC, Dapunt O, Hetzel H, Reibnegger G, Wachter H. Second-look operation in women with ovarian cancer: I. Concentrations of neopterin in urine and CA125 in serum at second-look laparotomy. Their relationship with prognosis. TumorDiagn Ther 1990; 11: 147-151.
23. Gadducci A, Ferdeghini M, Malagnino G, et al. Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer. Gyn Oncol 1994; 52: 386-391.
24. Bichler A, Fuchs D, Hausen A, Hetzel H, Konig K, Wachter H. Urinary neopterin excretion in patients with genital cancer. Clin Biochem 1982; 15: 38-40.
25. Hetzel H, Bichler A, Fuchs D, Hausen A, Reibnegger G, Wachter H. Significance of urinary neopterin in gynecological oncology: Follow-up of patients with ovarian cancer. Cancer Detect Prev 1983; 6: 263-266.
26. Miller BE, Pittman B, Wan JY, Fleming M. Colon cancer with metastasis to the ovary at time of initial diagnosis. Gyn Oncol 1997; 66: 368-371.
27. Kim HK, Heo DS, Bang YJ, Kim NK. Prognostic factors of Krukenberg's tumor. Gyn Oncol 2001; 82: 105-109.
28. Mullins DW, Burger CJ, Elgert KD. Paclitaxel enhances macrophage IL-12 production in tumor-bearing hosts through nitric oxide. J Immunol 1999; 162: 6811-6818.
29. Ranjan P, Sodhi A, Sristava A. Cisplatin and interferon-gamma treated murine macrophages induce apoptosis in tumor cell lines. Anti-Cancer Drugs 1997; 8: 797-806.
30. Rivory LP, Slaviero KA, Clarke SJ. Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br J Cancer 2002; 87: 277-280.
31. Zeimet AG, Windschwendter M, Uhl-Steidl M, et al. High serum levels of soluble CD44 variant isoform v5 are associated with favourable clinical outcome in ovarian cancer. Br J Cancer 1997; 76: 1646 -1651.
32. Rollins NC, Filteau SM, Coutsoudis A, Tomkins AM. Feeding mode, intestinal permeability, and neopterin excretion: a longitudinal study in infants of HIV-infected South African women. J Acquir Immune Defic Syndr 2001; 28: 132-139.
33. Parrilli G, Iaffaioli RV, Martorano M, et al. Effects of anthracycline therapy on intestinal absorption in patients with advanced breast cancer. Cancer Res 1989;49:3689-3691.
34. Sundstrom GM, Wahlin A, Nordin-Anderson I, Suhr OB. Intestinal permeability in patients with acute myeloid leukemia. Eur J Haematol 1998; 61: 250-254.
35. Melichar B, Dvorak J, Hyspler R, Zadak Z. Intestinal permeability in the assessment of intestinal toxicity of cytotoxic agents. Chemotherapy 2005; 51: 336-338.
36. van der Hulst RRWJ, von Meyenfeldt MF, van Kreel BK, et al. Gut permeability, intestinal morphology, and nutritional depletion. Nutrition 1998; 14: 1-6.
37. Parker D, Bradley C, Bogle SM, et al. Serum albumin and CA125 are powerful predictors of survival in epithelial ovarian cancer. Br J Obstet Gynaecol 1994; 101: 888-893.
38. Clark TG, Stewart ME, Altman DG, Gabra H, Smyth JF. A prognostic model for ovarian cancer. Br J Cancer 2001; 85: 944-952.